Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database

Korea Central Cancer Registry

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Aim:: We aimed to subclassify hepatocellular carcinoma (HCC) using Barcelona Clinic Liver Cancer intermediate and advanced stages, which include a highly heterogeneous population. Methods:: From two registries ("random" and "voluntary" cohorts in the Korean Liver Cancer Study Group), patients who were newly diagnosed as HCC with intermediate or advanced stage between 2003 and 2005 were considered eligible. Overall survival (OS) was analyzed using Kaplan-Meier method with comparison by log-rank test. Results:: Patients with intermediate-stage HCC (n=994) were subclassified according to tumor size and Child-Pugh class. Patients with tumor size<5cm (B1), those with tumor size≥5cm and Child-Pugh A (B2), and those with tumor size≥5cm and Child-Pugh B (B3) had median OS of 30.73, 20.60, and 9.23months, respectively (P<0.001 by log-rank test). Among patients with advanced stage HCC (n=1746), patients were subclassified according to presence of significant portal vein invasion (sPVI; defined as portal vein invasion in lobar, main, or contralateral branch) and extrahepatic spread (EHS). Patients with neither sPVI nor EHS (C1), those with either sPVI or EHS (C2), and those with both sPVI and EHS (C3) had median OS of 8.43, 4.63, and 3.63months, respectively (P<0.001 by log-rank test). Conclusion:: Subclassification of Barcelona Clinic Liver Cancer intermediate and advanced stages might be useful for determining patient prognosis and guiding treatment strategies for HCC.

Original languageEnglish
Pages (from-to)842-847
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume31
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Liver Neoplasms
Registries
Hepatocellular Carcinoma
Cohort Studies
Databases
Portal Vein
Survival
Neoplasms
Population

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{6b77ff77178442e084adad01d6e67169,
title = "Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database",
abstract = "Background and Aim:: We aimed to subclassify hepatocellular carcinoma (HCC) using Barcelona Clinic Liver Cancer intermediate and advanced stages, which include a highly heterogeneous population. Methods:: From two registries ({"}random{"} and {"}voluntary{"} cohorts in the Korean Liver Cancer Study Group), patients who were newly diagnosed as HCC with intermediate or advanced stage between 2003 and 2005 were considered eligible. Overall survival (OS) was analyzed using Kaplan-Meier method with comparison by log-rank test. Results:: Patients with intermediate-stage HCC (n=994) were subclassified according to tumor size and Child-Pugh class. Patients with tumor size<5cm (B1), those with tumor size≥5cm and Child-Pugh A (B2), and those with tumor size≥5cm and Child-Pugh B (B3) had median OS of 30.73, 20.60, and 9.23months, respectively (P<0.001 by log-rank test). Among patients with advanced stage HCC (n=1746), patients were subclassified according to presence of significant portal vein invasion (sPVI; defined as portal vein invasion in lobar, main, or contralateral branch) and extrahepatic spread (EHS). Patients with neither sPVI nor EHS (C1), those with either sPVI or EHS (C2), and those with both sPVI and EHS (C3) had median OS of 8.43, 4.63, and 3.63months, respectively (P<0.001 by log-rank test). Conclusion:: Subclassification of Barcelona Clinic Liver Cancer intermediate and advanced stages might be useful for determining patient prognosis and guiding treatment strategies for HCC.",
author = "{Korea Central Cancer Registry} and Sangheun Lee and Kim, {Beom Kyung} and Kijun Song and Junyong Park and SangHoon Ahn and Seungup Kim and KwangHyub Han and doyoung kim",
year = "2016",
month = "4",
day = "1",
doi = "10.1111/jgh.13218",
language = "English",
volume = "31",
pages = "842--847",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "4",

}

Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma : A cohort study of the multicenter registry database. / Korea Central Cancer Registry.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 31, No. 4, 01.04.2016, p. 842-847.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma

T2 - A cohort study of the multicenter registry database

AU - Korea Central Cancer Registry

AU - Lee, Sangheun

AU - Kim, Beom Kyung

AU - Song, Kijun

AU - Park, Junyong

AU - Ahn, SangHoon

AU - Kim, Seungup

AU - Han, KwangHyub

AU - kim, doyoung

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background and Aim:: We aimed to subclassify hepatocellular carcinoma (HCC) using Barcelona Clinic Liver Cancer intermediate and advanced stages, which include a highly heterogeneous population. Methods:: From two registries ("random" and "voluntary" cohorts in the Korean Liver Cancer Study Group), patients who were newly diagnosed as HCC with intermediate or advanced stage between 2003 and 2005 were considered eligible. Overall survival (OS) was analyzed using Kaplan-Meier method with comparison by log-rank test. Results:: Patients with intermediate-stage HCC (n=994) were subclassified according to tumor size and Child-Pugh class. Patients with tumor size<5cm (B1), those with tumor size≥5cm and Child-Pugh A (B2), and those with tumor size≥5cm and Child-Pugh B (B3) had median OS of 30.73, 20.60, and 9.23months, respectively (P<0.001 by log-rank test). Among patients with advanced stage HCC (n=1746), patients were subclassified according to presence of significant portal vein invasion (sPVI; defined as portal vein invasion in lobar, main, or contralateral branch) and extrahepatic spread (EHS). Patients with neither sPVI nor EHS (C1), those with either sPVI or EHS (C2), and those with both sPVI and EHS (C3) had median OS of 8.43, 4.63, and 3.63months, respectively (P<0.001 by log-rank test). Conclusion:: Subclassification of Barcelona Clinic Liver Cancer intermediate and advanced stages might be useful for determining patient prognosis and guiding treatment strategies for HCC.

AB - Background and Aim:: We aimed to subclassify hepatocellular carcinoma (HCC) using Barcelona Clinic Liver Cancer intermediate and advanced stages, which include a highly heterogeneous population. Methods:: From two registries ("random" and "voluntary" cohorts in the Korean Liver Cancer Study Group), patients who were newly diagnosed as HCC with intermediate or advanced stage between 2003 and 2005 were considered eligible. Overall survival (OS) was analyzed using Kaplan-Meier method with comparison by log-rank test. Results:: Patients with intermediate-stage HCC (n=994) were subclassified according to tumor size and Child-Pugh class. Patients with tumor size<5cm (B1), those with tumor size≥5cm and Child-Pugh A (B2), and those with tumor size≥5cm and Child-Pugh B (B3) had median OS of 30.73, 20.60, and 9.23months, respectively (P<0.001 by log-rank test). Among patients with advanced stage HCC (n=1746), patients were subclassified according to presence of significant portal vein invasion (sPVI; defined as portal vein invasion in lobar, main, or contralateral branch) and extrahepatic spread (EHS). Patients with neither sPVI nor EHS (C1), those with either sPVI or EHS (C2), and those with both sPVI and EHS (C3) had median OS of 8.43, 4.63, and 3.63months, respectively (P<0.001 by log-rank test). Conclusion:: Subclassification of Barcelona Clinic Liver Cancer intermediate and advanced stages might be useful for determining patient prognosis and guiding treatment strategies for HCC.

UR - http://www.scopus.com/inward/record.url?scp=84963799244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963799244&partnerID=8YFLogxK

U2 - 10.1111/jgh.13218

DO - 10.1111/jgh.13218

M3 - Article

C2 - 26513311

AN - SCOPUS:84963799244

VL - 31

SP - 842

EP - 847

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 4

ER -